Literature DB >> 28737579

Prostate-Specific Membrane Antigen-Targeted Imaging With [18F]DCFPyL in High-Grade Gliomas.

Roberto Andres Salas Fragomeni1, Joshua R Menke, Matthias Holdhoff, Clare Ferrigno, John Joseph Laterra, Lilja B Solnes, Mehrbod S Javadi, Zsolt Szabo, Martin G Pomper, Steven P Rowe.   

Abstract

High-grade gliomas (World Health Organization grade III-IV) are highly lethal primary brain tumors. Imaging modalities, including MRI and FDG PET, provide a limited ability to differentiate treatment effects (such as radiation necrosis) from recurrent or residual tumor. As the first step in validating the applicability of prostate-specific membrane antigen (PSMA)-targeted imaging in high-grade gliomas, we evaluated the ability of the PSMA-targeted small molecule [F]DCFPyL (2-(3-(1carboxy-5-(6-[F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid) to image high-grade gliomas in a series of 3 prospectively recruited patients. We found [F]DCFPyL binds PSMA in the neovasculature of glioblastoma multiforme and tumor cells of anaplastic astrocytoma.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28737579      PMCID： PMC5802343          DOI： 10.1097/RLU.0000000000001769

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

1.  2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Authors:  Ying Chen; Mrudula Pullambhatla; Catherine A Foss; Youngjoo Byun; Sridhar Nimmagadda; Srinivasan Senthamizhchelvan; George Sgouros; Ronnie C Mease; Martin G Pomper
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

2.  In vivo visualization of prostate-specific membrane antigen in glioblastoma.

Authors:  Johannes Schwenck; Ghazaleh Tabatabai; Marco Skardelly; Gerhald Reischl; Rudi Beschorner; Bernd Pichler; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-08       Impact factor: 9.236

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme.

Authors:  A Gabriella Wernicke; Mark A Edgar; Ehud Lavi; He Liu; Pamela Salerno; Neil H Bander; Philip H Gutin
Journal:  Arch Pathol Lab Med       Date:  2011-11       Impact factor: 5.534

5.  Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer.

Authors:  Zsolt Szabo; Esther Mena; Steven P Rowe; Donika Plyku; Rosa Nidal; Mario A Eisenberger; Emmanuel S Antonarakis; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Melin Vranesic; Akrita Bhatnagar; George Sgouros; Steve Y Cho; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2015-08       Impact factor: 3.488

6.  Diagnostic Value of 68Ga PSMA-11 PET/CT Imaging of Brain Tumors-Preliminary Analysis.

Authors:  Arun Sasikumar; Ajith Joy; M R A Pillai; Raviteja Nanabala; Muhammed Anees K; P G Jayaprakash; Jayaprakash Madhavan; Suresh Nair
Journal:  Clin Nucl Med       Date:  2017-01       Impact factor: 7.794

7.  Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique.

Authors:  P Mhawech-Fauceglia; S Zhang; L Terracciano; G Sauter; A Chadhuri; F R Herrmann; R Penetrante
Journal:  Histopathology       Date:  2007-03       Impact factor: 5.087

8.  Prostate specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases.

Authors:  Natsuko Nomura; Sandra Pastorino; Pengfei Jiang; Gage Lambert; John R Crawford; Marco Gymnopoulos; David Piccioni; Tiffany Juarez; Sandeep C Pingle; Milan Makale; Santosh Kesari
Journal:  Cancer Cell Int       Date:  2014-03-20       Impact factor: 5.722
  8 in total
  21 in total

1.  Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy.

Authors:  Jolanta Kunikowska; Królicki Bartosz; Królicki Leszek
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-31       Impact factor: 9.236

Review 2.  Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.

Authors:  Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-01-15       Impact factor: 9.236

3.  Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients.

Authors:  Elisa Perry; Arpit Talwar; Sanjana Sharma; Daisy O'Connor; Lih-Ming Wong; Kim Taubman; Tom R Sutherland
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-03-07       Impact factor: 10.057

4.  Sigma-1 Receptor Positron Emission Tomography: A New Molecular Imaging Approach Using (S)-(-)-[18F]Fluspidine in Glioblastoma.

Authors:  Magali Toussaint; Winnie Deuther-Conrad; Mathias Kranz; Steffen Fischer; Friedrich-Alexander Ludwig; Tareq A Juratli; Marianne Patt; Bernhard Wünsch; Gabriele Schackert; Osama Sabri; Peter Brust
Journal:  Molecules       Date:  2020-05-06       Impact factor: 4.411

5.  Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.

Authors:  Krissie Lenting; Corina N A M van den Heuvel; Anne van Ewijk; Duaa ElMelik; Remco de Boer; Elizabeth Tindall; Ge Wei; Benno Kusters; Maarten Te Dorsthorst; Mark Ter Laan; Martijn A Huynen; William P Leenders
Journal:  Acta Neuropathol Commun       Date:  2019-11-20       Impact factor: 7.801

Review 6.  The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors.

Authors:  Ilanah J Pruis; Guus A M S van Dongen; Sophie E M Veldhuijzen van Zanten
Journal:  Int J Mol Sci       Date:  2020-02-04       Impact factor: 5.923

7.  PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?

Authors:  Winfried Brenner; Joachim Strobel; Vikas Prasad
Journal:  J Nucl Med       Date:  2021-07-16       Impact factor: 10.057

8.  Nonspecific Uptake of 68Ga-Prostate-Specific Membrane Antigen in Diseases other than Prostate Malignancy on Positron Emission Tomography/Computed Tomography Imaging: A Pictorial Assay and Review of Literature.

Authors:  Dharmender Malik; Apurva Sood; Bhagwant Rai Mittal; Harmandeep Singh; Rajender Kumar Basher; Jaya Shukla; Anish Bhattacharya; Shrawan Kumar Singh
Journal:  Indian J Nucl Med       Date:  2018 Oct-Dec

9.  Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain.

Authors:  Jayendrakishore Tanjore Ramanathan; Suvi Lehtipuro; Harri Sihto; József Tóvári; Lilla Reiniger; Vanda Téglási; Judit Moldvay; Matti Nykter; Hannu Haapasalo; Vadim Le Joncour; Pirjo Laakkonen
Journal:  J Cell Mol Med       Date:  2020-05-11       Impact factor: 5.310

Review 10.  PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.

Authors:  Christophe Van de Wiele; Mike Sathekge; Bart de Spiegeleer; Pieter Jan de Jonghe; Laurence Beels; Alex Maes
Journal:  Int J Mol Sci       Date:  2019-10-02       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.